Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has an approved product (Casgevy) and a deeper pipeline, versus Beam Therapeutics, a clinical-stage company with a potentially safer base-editing platform. CRISPR Therapeutics is recommended as the better investment due to its approved product, stronger cash position ($2.4B vs $1.2B), and deeper pipeline, making it less risky despite both stocks carrying clinical trial risks.